STOCK TITAN

REGEN BIOPHARMA PFD A - RGBPP STOCK NEWS

Welcome to our dedicated page for REGEN BIOPHARMA PFD A news (Ticker: RGBPP), a resource for investors and traders seeking the latest updates and insights on REGEN BIOPHARMA PFD A stock.

Regen BioPharma, Inc. focuses on the development of small molecule therapies for treating cancer and autoimmune disorders in the United States. The company's primary focus is on developing small molecule NR2F6 that activates immune cells for oncology and autoimmune diseases. Founded in 2012, the company is based in La Mesa, California, and is a subsidiary of Bio-Matrix Scientific Group, Inc.

Regen BioPharma, Inc. is currently advancing novel technologies through pre-clinical and Phase I/II clinical trials, with a specific emphasis on mRNA and small molecule therapies for cancer and autoimmune disorders.

Rhea-AI Summary

Regen BioPharma (RGBP) has provided updates on its planned Phase 1 clinical trial for HemaXellerate™, a stem cell-derived therapy that received FDA clearance. The therapy aims to stimulate bone marrow regeneration, initially targeting aplastic anemia with potential expansion into chemotherapy-induced bone marrow suppression. The company has partnered with a specialized CRO to conduct the trial, which is expected to complete within 12-14 months. The targeted market for chemotherapy-induced bone marrow suppression is valued at over $1 billion annually.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20%
Tags
-
Rhea-AI Summary

Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) will present at the Emerging Growth Conference on September 25, 2024, at 4:00 PM Eastern Time. The company, which focuses on developing cell therapies, RNA vaccines, RNA and DNA therapeutics, and small molecule drugs, invites investors, advisors, and analysts to attend this interactive online event.

CEO Dr. David Koos will lead the presentation, providing updates on fiscal and scientific goals, progress on current programs, and the timeline for the anticipated HemaXellerate clinical phase I. Attendees will have the opportunity to ask questions in real-time during the 10-minute presentation.

Interested parties can register for the event through the provided link. An archived webcast will be available on EmergingGrowth.com for those unable to attend live.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.43%
Tags
conferences
-
Rhea-AI Summary

Regen BioPharma, Inc. is set to present at the Emerging Growth Conference on May 9, 2024, offering shareholders and investors insights into its Phase 1 clinical study-ready HemaXellerate and preclinical DuraCAR programs. The event aims to provide real-time interaction with the CEO, Dr. David Koos, enabling attendees to ask questions and stay updated on the company's advancements in biotechnology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.92%
Tags
conferences
Rhea-AI Summary
Regen BioPharma, Inc. (RGBP) to present at the Emerging Growth Conference, focusing on advancing HemaXellerate into Phase 1 trials. CEO Dr. David Koos to interact with shareholders and investors in real time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.19%
Tags
-
Rhea-AI Summary
Regen BioPharma, Inc. (RGBP) is set to present at the Emerging Growth Conference on February 7, 2024, offering shareholders and investors the chance to interact with CEO Dr. David Koos. The company will update on fiscal and scientific goals, introduce a new scientific consultant, and discuss progress on the DuraCAR program. The event will cover the diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics, and small molecule drugs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
conferences acquisition
-
Rhea-AI Summary
Regen BioPharma, Inc. (RGBP) to Present at Emerging Growth Conference, CEO Dr. David Koos to Discuss Fiscal and Scientific Goals
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.11%
Tags
conferences acquisition
Rhea-AI Summary
Regen BioPharma, Inc. (RGBP) invites investors to its real-time, interactive presentation at the Emerging Growth Conference. The company, a biotechnology firm, will discuss progress and financial plan updates, including its DuraCAR program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
conferences acquisition
-
Rhea-AI Summary
Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has announced the selection of a Contract Research Organization (CRO) to conduct in vitro studies on the effectiveness of its DuraCAR cells. The experiments will focus on the immunosuppressive and tumor-killing capabilities of the cells, aiming to determine their potential in cancer treatment. Dr. David Koos, Chairman and CEO, expressed confidence in the chosen CRO and expects the results to provide valuable insights for the program's advancement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
none
-
Rhea-AI Summary
Regen BioPharma, Inc. (OTC PINK: RGBP) will be presenting at the Emerging Growth Conference on November 1, 2023. The online event will allow shareholders and the investment community to interact with the CEO, Dr. David Koos, in real time. The company will discuss recent scientific results and provide updates on its financial plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
Rhea-AI Summary
Regen BioPharma receives confirmatory data on its DuraCAR CAR T-cell therapy targeting autoimmunity. The data shows high expression levels of NR2F6 mRNA, which is an immune checkpoint. The company plans to design T cells to suppress immune activation in autoimmune disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.72%
Tags
none

FAQ

What is the current stock price of REGEN BIOPHARMA PFD A (RGBPP)?

The current stock price of REGEN BIOPHARMA PFD A (RGBPP) is $0.0804 as of November 22, 2024.

What is the market cap of REGEN BIOPHARMA PFD A (RGBPP)?

The market cap of REGEN BIOPHARMA PFD A (RGBPP) is approximately 6.5M.

What is Regen BioPharma, Inc.'s primary focus?

The company focuses on developing small molecule therapies for treating cancer and autoimmune disorders.

When was Regen BioPharma, Inc. founded?

Regen BioPharma, Inc. was founded in 2012.

Where is Regen BioPharma, Inc. based?

The company is based in La Mesa, California.

What kind of technologies is Regen BioPharma, Inc. advancing?

Regen BioPharma, Inc. is advancing novel technologies through pre-clinical and Phase I/II clinical trials.

What are the specific therapeutic areas Regen BioPharma, Inc. is focusing on?

The company is focused on developing mRNA and small molecule therapies for treating cancer and autoimmune disorders.

REGEN BIOPHARMA PFD A

OTC:RGBPP

RGBPP Rankings

RGBPP Stock Data

6.53M
1.23M
0%
Biotechnology
Healthcare
Link
United States of America
La Mesa